Primary large B‐cell lymphoma of the central nervous system: A reappraisal of CD5‐positive cases based on clinical, pathological, and molecular evaluation
Pathology International · 2025
DOI: 10.1111/pin.13496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology International, 2025. Verfasst von Seiji Yamada und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Analytical Pathology, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University School of Medicine, Toyoake, …. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, CD5 Antigens, Central Nervous System Neoplasms. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
CD5 expression is seen in 5%–10% of de novo diffuse large B‐cell lymphomas (DLBCLs). Primary large B‐cell lymphoma of the central nervous system (PCNS‐LBCL) also exhibits CD5 expression in a minority of cases, however, clinicopathological and molecular features remain largely unclarified. Here we present the clinical, molecular, and pathological features of 11 CD5‐positive ( + ) PCNS‐LBCL cases, occupying 6.7% of all 165 PCNS‐LBCLs diagnosed in our institutions. While CD5 + systemic DLBCL has been recognized as a distinctive subgroup showing an aggressive clinical course, no obvious differences were found between CD5 + and CD5‐negative subgroups among the present CNS patients clinically. MYD88 p.L265P and CD79B p.Y196 mutations were detected in eight (73%) and seven (64%) cases, respectively, supporting previous reports. Notably, the microenvironmental immune cells were universally PD‐L1/CD274‐positive, and the higher levels tended to present favorable overall survival, as already evidenced in the PCNS‐LBCL series. In contrast, neoplastic PD‐L1/CD274 expression was undetectable in all cases. Indeed, no structural variations or copy number alterations involving PD‐1 ligands were detected by targeted‐capture sequencing and fluorescence in situ hybridization. While further studies are warranted, we may have confirmed similarity between PCNS‐LBCLs and intravascular large B‐cell lymphomas from a molecular standpoint.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Analytical Pathology, Oncology Innovation Center, Research Promotion Headquarters, Fujita Health University School of Medicine, Toyoake, Japan.
- Department of Neurosurgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan.
- Center for Clinical Pathology, Fujita Health University Hospital, Toyoake, Japan.
- Department of Hematology, Fujita Health University School of Medicine, Toyoake, Japan.
- Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Zitieren
APA
Yamada, S., Satou, A., Tsuyuki, Y., Iba, S., Okumura, Y., Ishikawa, E., Ito, H., Kogure, Y., Goto, N., Tanikawa, M., Shimada, K., Tsukamoto, T., Karube, K., Yokoo, H., Kataoka, K., Tomita, A., Mase, M., & Nakamura, S. (2025). Primary large B‐cell lymphoma of the central nervous system: A reappraisal of CD5‐positive cases based on clinical, pathological, and molecular evaluation. Pathology International. https://doi.org/10.1111/pin.13496
Vancouver
Yamada S, Satou A, Tsuyuki Y, Iba S, Okumura Y, Ishikawa E, et al. Primary large B‐cell lymphoma of the central nervous system: A reappraisal of CD5‐positive cases based on clinical, pathological, and molecular evaluation. Pathology International. 2025. doi:10.1111/pin.13496
BibTeX
@article{Yamada2025,
author = {Yamada, Seiji and Satou, Akira and Tsuyuki, Yuta and Iba, Sachiko and Okumura, Yuka and Ishikawa, Eri and Ito, Hideaki and Kogure, Yasunori and Goto, Naoe and Tanikawa, Motoki and Shimada, Kazuyuki and Tsukamoto, Tetsuya and Karube, Kennosuke and Yokoo, Hideaki and Kataoka, Keisuke and Tomita, Akihiro and Mase, Mitsuhito and Nakamura, Shigeo},
title = {Primary large B‐cell lymphoma of the central nervous system: A reappraisal of CD5‐positive cases based on clinical, pathological, and molecular evaluation},
journal = {Pathology International},
year = {2025},
doi = {10.1111/pin.13496}
}
EUVIMED